Form 4: Phillip Frost Reports Acquisition and Disposal of Cocrystal Pharma Stock

Phillip Frost reports acquiring 27,100 shares of Cocrystal Pharma stock and disposing of 27,100 shares in a transaction on October 9, 2024, while also detailing indirect ownership through Frost Gamma Investments Trust.

Summary

• On October 9, 2024, Phillip Frost acquired 27,100 shares of Cocrystal Pharma common stock.
• On October 9, 2024, Phillip Frost disposed of 27,100 shares of Cocrystal Pharma common stock.
• Frost's direct holdings following the transaction are 27,100 shares.
• He also indirectly owns 1,319,838 shares through Frost Gamma Investments Trust.
• The reported transactions involve restricted stock units (RSUs), with half already vested and the remainder vesting quarterly until September 30, 2025.
• Vesting is contingent upon continued service and accelerates upon a change of control.
• Frost disclaims beneficial ownership of shares held by OPKO Health, Inc., except for any pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions and ownership, with no inherent positive or negative sentiment.

Future Outlook

The remaining RSUs will vest in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.

Management Comments

• Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein.
• Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders, providing transparency into their transactions in company stock.

Key Dates